Wellington Management Group LLP Has $2.54 Million Stock Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Wellington Management Group LLP cut its holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 22.7% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 88,591 shares of the specialty pharmaceutical company's stock after selling 26,049 shares during the period. Wellington Management Group LLP owned about 0.28% of Collegium Pharmaceutical worth $2,538,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. Invesco Ltd. increased its position in Collegium Pharmaceutical by 19.5% in the fourth quarter. Invesco Ltd. now owns 1,775,760 shares of the specialty pharmaceutical company's stock worth $50,876,000 after buying an additional 289,335 shares during the period. Janus Henderson Group PLC grew its position in shares of Collegium Pharmaceutical by 319.4% during the fourth quarter. Janus Henderson Group PLC now owns 291,388 shares of the specialty pharmaceutical company's stock worth $8,341,000 after acquiring an additional 221,903 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in shares of Collegium Pharmaceutical in the 4th quarter worth about $3,489,000. Raymond James Financial Inc. bought a new stake in Collegium Pharmaceutical in the 4th quarter valued at about $2,432,000. Finally, F M Investments LLC bought a new stake in Collegium Pharmaceutical in the 4th quarter valued at about $2,096,000.

Insider Activity

In related news, CFO Colleen Tupper sold 977 shares of the firm's stock in a transaction that occurred on Friday, March 14th. The shares were sold at an average price of $30.00, for a total transaction of $29,310.00. Following the completion of the sale, the chief financial officer now directly owns 164,269 shares in the company, valued at approximately $4,928,070. This trade represents a 0.59% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Scott Dreyer sold 2,255 shares of the company's stock in a transaction on Friday, March 14th. The shares were sold at an average price of $30.00, for a total value of $67,650.00. Following the completion of the transaction, the executive vice president now directly owns 124,421 shares in the company, valued at $3,732,630. This represents a 1.78% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 13,677 shares of company stock worth $410,414 over the last 90 days. 2.51% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several equities research analysts have commented on COLL shares. HC Wainwright restated a "buy" rating and issued a $50.00 price target on shares of Collegium Pharmaceutical in a research note on Monday, March 24th. Needham & Company LLC restated a "buy" rating and issued a $46.00 target price on shares of Collegium Pharmaceutical in a research report on Wednesday, April 9th. Piper Sandler reaffirmed a "neutral" rating and set a $37.00 target price (up previously from $36.00) on shares of Collegium Pharmaceutical in a research note on Friday, May 9th. Finally, Wall Street Zen cut Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a research note on Saturday, April 19th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Collegium Pharmaceutical currently has an average rating of "Moderate Buy" and an average target price of $43.75.

Collegium Pharmaceutical Price Performance

Shares of NASDAQ:COLL traded up $0.24 during trading on Monday, reaching $30.44. The company had a trading volume of 360,727 shares, compared to its average volume of 415,901. The firm's fifty day moving average is $28.01 and its 200 day moving average is $29.59. The company has a debt-to-equity ratio of 3.43, a quick ratio of 0.88 and a current ratio of 0.97. The firm has a market capitalization of $978.10 million, a PE ratio of 13.12 and a beta of 0.63. Collegium Pharmaceutical, Inc. has a twelve month low of $23.23 and a twelve month high of $42.29.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last released its earnings results on Thursday, May 8th. The specialty pharmaceutical company reported $1.49 earnings per share for the quarter, missing analysts' consensus estimates of $1.50 by ($0.01). The firm had revenue of $177.76 million during the quarter, compared to analyst estimates of $174.96 million. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. The business's revenue for the quarter was up 22.7% on a year-over-year basis. During the same quarter last year, the company earned $1.45 earnings per share. On average, equities analysts forecast that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current year.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.